Verastem: Peers

The FY2025 (Dec) proxy of Verastem names 17 peer companies for pay. Among Verastem and these peers, CEO pay was the lowest of 6 and total shareholder return was 5th highest of 6.

6th highest of 6in Verastem and its pay peers, FY2025 (Dec) by CEO pay:

$2.3M$33.3M

5th highest of 6in Verastem and its pay peers, FY2025 (Dec) by total shareholder return:

$84$1,020

Pay peer group, FY2025 (Dec) proxy

Scholar Rock Holding
Cogent Biosciences
Compass Therapeutics
Kura Oncology
Olema Pharmaceuticals
Acrivon Therapeutics, Inc.Not disclosedNot disclosed
Actinium Pharmaceuticals, Inc.Not disclosedNot disclosed
Aura BiosciencesNot disclosedNot disclosed
Cardiff OncologyNot disclosedNot disclosed
CelcuityNot disclosedNot disclosed
Cullinan Oncology, Inc.Not disclosedNot disclosed
Leap Therapeutics, Inc.Not disclosedNot disclosed
Lian BioNot disclosedNot disclosed
MEI Pharma, Inc.Not disclosedNot disclosed
Syros Pharmaceuticals, Inc.Not disclosedNot disclosed
Terns Pharmaceuticals, Inc.Not disclosedNot disclosed
iTeos Therapeutics, Inc.Not disclosedNot disclosed
17 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.